Metraipolis › archive › dc_4bac46d65fa4
Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single… — Europe PMC PMID:41583497
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41583497
- DOI
- 10.3389/fimmu.2025.1710017
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T00:04:06.629Z
- SHA-256 of the archived text
378ffd13f612a0b1189877d21882148567fb232ce9386ea368a9955fe9bbec73- Stable URL of this page
https://metraipolis.com/documento/dc_4bac46d65fa4
How to cite
Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single… — Europe PMC PMID:41583497 — Europe PMC (en), https://europepmc.org/article/MED/41583497 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4bac46d65fa4 (Metraipolis archive dc_4bac46d65fa4, sha256 378ffd13f612a0b1189877d21882148567fb232ce9386ea368a9955fe9bbec73)
BibTeX
@misc{dc4bac46d65fa4,
title = {Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single… — Europe PMC PMID:41583497},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41583497},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4bac46d65fa4; sha256 378ffd13f612a0b1189877d21882148567fb232ce9386ea368a9955fe9bbec73},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41583497. Agents can read the archived copy with the MCP tool read_document.